Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sumatriptan for blood glucose lowering in overweight/obese individuals
NCT04690270Phase 1Unknown
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
- Start
- Jan 2021
- Primary completion
- Jun 2021
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of sumatriptan in type 2 diabetes mellitus (T2DM) and type 1 diabetes mellitus (T1D), sponsored by Cambridge University Hospitals NHS Foundation Trust. Primary endpoint: Insulin sensitivity at 4 weeks. Status: unknown.
02
Drugs
sumatriptan
03
Conditions
type 2 diabetes mellitus (T2DM)type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT04690270.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04690270.